

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROFIT WARNING

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wish to inform the shareholders and potential investors of the Company that, based on the unaudited consolidated management accounts of the Company for the six months ended 30 June 2020 prepared in accordance with Hong Kong Financial Reporting Standards, the net profit of the Group for the six months ended 30 June 2020 is expected to be approximately RMB200 million, while the net profit for the six months ended 30 June 2019 is approximately RMB295.9 million.

The decrease in net profit is mainly due to loss on fair value change of embedded derivative components of convertible bonds of approximately RMB220 million (2019: gain of approximately RMB52.4 million), which is a non-cash item having no impact to the Group’s liquidity position.

Excluding the fair value changes arising from convertible bonds and investment properties, the operating profit from core business for the six months ended 30 June 2020 is approximately RMB400 million as compared to approximately RMB336.9 million of same period in 2019. The increase in operating results is mainly contributed from increase in revenue, and decrease in operating expenses and finance costs during the reporting period.

The information in this announcement is only based on the information currently available to the management. The results of the Group for the six months ended 30 June 2020 have not yet been finalised nor reviewed by the Company’s audit committee and auditor. The final results of the Group for the six months ended 30 June 2020 may be different to the information referred in this announcement.

Detailed unaudited interim results of the Group for the six months ended 30 June 2020 will be published in the forthcoming 2020 interim results announcement and interim report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 17 August 2020

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.